No, the shingles vaccine does not provide complete protection against shingles
The recombinant zoster vaccine (Shingrix/RZV) provides approximately 97% protection against shingles in adults aged 50 years and older, which is highly effective but not complete. 1
Vaccine Efficacy by Type
Recombinant Zoster Vaccine (Shingrix/RZV) - Preferred Option
The RZV demonstrates the highest protection rates:
- Overall efficacy: 97.2% in adults aged 50+ years (ZOE-50 trial) 1
- 89.8% efficacy in adults aged 70+ years (ZOE-70 trial) 1
- 91.3% protection against shingles and 88.8% against postherpetic neuralgia (PHN) in pooled analysis of adults ≥70 years 1
The protection remains durable but gradually declines:
- Maintained above 83.3% for up to 8 years 1
- Decreases to 73% at 10 years 1
- Recent meta-analysis suggests protection for at least 11 years 2
Live Attenuated Vaccine (Zostavax/ZVL) - Less Effective
The older ZVL vaccine shows substantially lower efficacy:
- 51.3% efficacy for preventing shingles in adults aged 60+ years 1
- 69.8% efficacy in adults aged 50-59 years 1
- Efficacy decreases significantly with age: 70% (ages 50-59), 64% (ages 60-69), 41% (ages 70-79), and only 18% (ages 80+) 1
- Protection wanes dramatically over time: drops from 51.3% to 21.2% for shingles incidence during 7-11 years post-vaccination 1
Clinical Implications
Even vaccinated individuals can still develop shingles, though the risk is substantially reduced. Among the small percentage who do develop breakthrough shingles after RZV vaccination, the vaccine is associated with:
- Reduced loss of quality of life 2
- Decreased analgesic use 2
- Substantially reduced risk of herpes zoster ophthalmicus 2
- Likely reduced risk of postherpetic neuralgia 2
Guideline Recommendations
RZV is strongly recommended for immunocompetent adults aged 50 years and older (Strong recommendation, moderate quality of evidence) 1. The 2024 Taiwan guidelines explicitly state a preference for RZV over ZVL due to its superior efficacy across all age groups and longer duration of protection 1.
Common Pitfall to Avoid
Do not tell patients the vaccine provides "complete" or "100%" protection. Set realistic expectations: approximately 3 out of 100 vaccinated individuals may still develop shingles, but the vaccine dramatically reduces this risk and lessens severity if breakthrough infection occurs.